Published in Mol Pharmacol on August 26, 2005
The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes Dev (2007) 3.58
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell (2016) 2.08
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther (2009) 1.66
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest (2012) 1.49
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol (2009) 1.33
Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther (2013) 1.16
Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability. J Cell Biol (2008) 1.14
ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene (2011) 1.09
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol (2009) 1.08
Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res (2008) 1.07
CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res (2011) 1.06
Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res (2008) 1.05
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res (2012) 1.01
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs (2012) 1.01
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia (2012) 0.97
Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. Mol Pharmacol (2012) 0.95
Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci U S A (2013) 0.94
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs (2014) 0.92
ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res (2008) 0.91
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol (2011) 0.89
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One (2011) 0.89
Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol Cancer Ther (2011) 0.88
DNA polymerase eta and chemotherapeutic agents. Antioxid Redox Signal (2011) 0.86
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. J Cell Mol Med (2013) 0.84
Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity. DNA Repair (Amst) (2013) 0.84
Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potential. PLoS One (2013) 0.80
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. BMC Cancer (2014) 0.80
Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PLoS One (2014) 0.79
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Invest New Drugs (2015) 0.79
Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn (2015) 0.78
Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines. Mol Pharmacol (2008) 0.78
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. J Cancer (2016) 0.77
Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals (Basel) (2010) 0.77
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemother Pharmacol (2015) 0.77
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Invest New Drugs (2015) 0.76
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. Cell Cycle (2016) 0.75
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res (2017) 0.75
miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch (2017) 0.75
RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell (2007) 8.71
Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell (2006) 8.12
The BRCT domain is a phospho-protein binding domain. Science (2003) 7.42
PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70
MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell (2006) 6.09
Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science (2007) 5.88
DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol (2002) 5.85
DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol (2004) 4.78
DBC1 is a negative regulator of SIRT1. Nature (2008) 4.66
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol (2008) 4.56
Genomic instability in laminopathy-based premature aging. Nat Med (2005) 4.54
p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol (2003) 4.36
Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol (2008) 3.94
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature (2006) 3.90
BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol (2009) 3.79
The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes Dev (2007) 3.58
53BP1 is required for class switch recombination. J Cell Biol (2004) 3.57
H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell (2006) 3.53
BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev (2006) 3.44
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J Biol Chem (2003) 3.34
Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell (2010) 3.33
MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature (2003) 3.00
PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A (2009) 2.98
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol Cell (2007) 2.88
FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science (2010) 2.80
UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation requires replication stress. J Biol Chem (2004) 2.72
Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol (2012) 2.70
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
RAD18 transmits DNA damage signalling to elicit homologous recombination repair. Nat Cell Biol (2009) 2.67
19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J (2007) 2.63
Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair (Amst) (2004) 2.55
CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol (2007) 2.55
Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J Biol Chem (2003) 2.50
MERIT40 facilitates BRCA1 localization and DNA damage repair. Genes Dev (2009) 2.49
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem (2003) 2.40
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol (2009) 2.27
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
The annealing helicase HARP protects stalled replication forks. Genes Dev (2009) 2.19
Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol (2006) 2.18
Efficacy of bipolar radiofrequency endometrial ablation vs thermal balloon ablation for management of menorrhagia: A population-based cohort. J Minim Invasive Gynecol (2009) 2.09
A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival. Mol Cell Biol (2002) 2.09
Enhanced recovery in gynecologic surgery. Obstet Gynecol (2013) 2.07
Mechanism of radiation-induced bystander effects: a unifying model. J Pharm Pharmacol (2008) 2.07
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Human claspin is required for replication checkpoint control. J Biol Chem (2003) 2.02
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res (2011) 2.02
Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J Biol Chem (2003) 2.00
WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol (2011) 2.00
Enhanced intra-switch region recombination during immunoglobulin class switch recombination in 53BP1-/- B cells. Eur J Immunol (2007) 1.98
Chfr is required for tumor suppression and Aurora A regulation. Nat Genet (2005) 1.97
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem (2010) 1.95
Current management strategies for ovarian cancer. Mayo Clin Proc (2007) 1.94
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol (2010) 1.94
Direct interaction between SET8 and proliferating cell nuclear antigen couples H4-K20 methylation with DNA replication. J Biol Chem (2008) 1.93
Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway. Proc Natl Acad Sci U S A (2005) 1.92
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res (2012) 1.87
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood (2009) 1.86
RIF1 counteracts BRCA1-mediated end resection during DNA repair. J Biol Chem (2013) 1.86
Mammalian Rad9 plays a role in telomere stability, S- and G2-phase-specific cell survival, and homologous recombinational repair. Mol Cell Biol (2006) 1.84
Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J (2002) 1.82
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol (2004) 1.82
Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure (2004) 1.82
The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J Biol Chem (2001) 1.82
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer (2008) 1.80
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem (2003) 1.80
The DNA damage response pathways: at the crossroad of protein modifications. Cell Res (2008) 1.80
Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat Cell Biol (2009) 1.79
Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol (2006) 1.77
Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol (2011) 1.73
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem (2001) 1.72
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol (2006) 1.70
Prediction of treatment outcomes after global endometrial ablation. Obstet Gynecol (2009) 1.67
Image-based models of cardiac structure in health and disease. Wiley Interdiscip Rev Syst Biol Med (2010) 1.67
Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol (2004) 1.66
BACH1/FANCJ acts with TopBP1 and participates early in DNA replication checkpoint control. Mol Cell (2010) 1.65
The tandem BRCT domains of Ect2 are required for both negative and positive regulation of Ect2 in cytokinesis. J Biol Chem (2004) 1.64
The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. Nat Struct Mol Biol (2012) 1.64
Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem (2004) 1.63
Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. Mol Cell Biol (2004) 1.63
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63
SOSS complexes participate in the maintenance of genomic stability. Mol Cell (2009) 1.63
MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc Natl Acad Sci U S A (2008) 1.63
The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol (2010) 1.61
Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res (2007) 1.60
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
BRCA1 participates in DNA decatenation. Nat Struct Mol Biol (2005) 1.59
Focus on histone variant H2AX: to be or not to be. FEBS Lett (2010) 1.56